A federal judge in Riverside declared a California stem cell treatment firm to be exempt from Food and Drug Administration regulations, opening the door to the further proliferation of clinics offering therapies the FDA says are scientifically unproven and potentially dangerous.
In the ruling issued late Tuesday, Judge Jesus G. Bernal of Riverside declined to block California Stem Cell Treatment Center from continuing to offer purported stem cell treatments to customers.
Bernal accepted the centers position that its treatments qualified for an exception from FDA regulations, in part because they were tantamount to surgical procedures.
Stem cells have been called everything from cure-alls to miracle treatments. But dont believe the hype.
Food and Drug Administration warns public against unproven stem cell treatments
Bernals ruling, which came more than a year after a seven-day trial in May 2021 and closing arguments last August, potentially undermines a years-long FDA crackdown on clinics claiming that stem cells can treat or cure conditions including orthopedic injuries, Alzheimers and Parkinsons diseases, multiple sclerosis, and erectile dysfunction.
The defendants are engaged in the practice of medicine, Bernal ruled, not the manufacture of pharmaceuticals.
The FDA regulations, however, define drugs much more broadly than the manufacture of pharmaceuticals rather, as any article that is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. Any such articles, the agency says, must have agency approval and the California centers treatments do not.
To me, the language of his ruling sounded almost like it was written by the defendants, Paul S. Knoepfler, a UC Davis stem cell biologist who has been tracking the proliferation of such clinics for years, observed in his laboratory blog.
Newsletter
Get the latest from Michael Hiltzik
Commentary on economics and more from a Pulitzer Prize winner.
Enter email address
Sign Me Up
You may occasionally receive promotional content from the Los Angeles Times.
The Bernal ruling will not be a good thing for careful oversight of stem cell clinic practices, Knoepfler said. Its concerning to think about more people being put at risk.
Knoepfler suggested that the FDA would feel duty-bound to appeal Bernals ruling in order to protect its regulatory campaign, and because it conflicts with federal court rulings in a nearly identical case the FDA brought against Florida clinics in Miami federal court.
The agency told me by email that it is reviewing the courts decision and does not have further comment at this time.
Bioethicist Leigh Turner of UC Irvine, who has collaborated with Knoepfler on tracking the growth of the stem cell clinic industry, agreed that Bernals ruling is an enormous setback for the FDA in an area where theyve struggled for many years.... For people who work in this industry, its great news. But not for anyone concerned about patient safety, misinformation or disinformation.
As part of its crackdown, the FDA has written hundreds of letters warning stem cell clinics that theyre violating the law, and has pursued some in court.
After issuing regulations in 2017 declaring that treatments using unproven stem cell therapies were illegal, the FDA suspended its enforcement for more than three years to give clinic operators time to comply with FDA rules. The agencys forbearance, however, opened the door to a further proliferation of suspect clinics.
By March 2021, according to a survey by Turner, nearly 1,500 U.S. businesses were pitching the suspect treatments at more than 2,700 clinics, reflecting a torrent of openings since 2016, when Turner and Knoepfler jointly started tracking the field.
More than four times as many businesses than were identified five years ago are selling stem cell products that are not FDA-approved and lack convincing evidence of safety and efficacy, Turner wrote last year.
Some clinics have charged customers more than $10,000 for the unproven treatments, plying the customers with unsupported claims of medical success. The fees are seldom, if ever, covered by health insurance. Some treatments resulted in serious medical complications.
The FDA also has warned the public that some patients seeking cures and remedies are vulnerable to stem cell treatments that are illegal and potentially harmful.
The FDA has approved stem cell treatments only for disorders of the blood-producing, or hematopoietic, system. No other stem cell treatment claims have been scientifically validated, the agency says.
Stem cells have been called everything from cure-alls to miracle treatments, the agency says in its public warning. But dont believe the hype.
Bernals ruling conflicts with a 2019 decision by U.S. District Judge Ursula Ungaro of Miami, who ordered a Florida clinic shut down after the FDA asserted that its purported stem cell therapies were scientifically unproven and illegal.
Ungaros decision was upheld last year by the 11th Circuit U.S. Court of Appeals, which found that the clinics claim of exemption from FDA regulation on grounds similar to those claimed by the California center, didnt apply. No reasonable fact-finder could disagree, the three-judge appellate panel ruled.
As it happens, in its finding the appellate panel specifically rejected an earlier ruling by Bernal, in which he denied the FDAs request for a preliminary injunction against the California center and set the case for trial. The appellate ruling isnt binding precedent for federal courts outside the 11th Circuit, which covers parts of the Southeast.
The FDAs lawsuits against the Florida clinic and the California center were almost identical and filed on the same day, May 9, 2018. In both cases, the agency asserted that the clinics were in effect purveying illegal drugs as defined by federal law.
The lawsuits were part of an agency effort to clamp down on the burgeoning trade in stem cell-related therapies. The California lawsuit named the centers founders, Elliott Lander and Mark Berman, as defendants. Berman died in April
The California Stem Cell Treatment Center has operated clinics in Beverly Hills and Rancho Mirage, and provides treatment protocols and other assistance to other clinics around the country.
In its Florida and California lawsuits, the FDA targeted a widespread practice utilized by both clinics in which fat cells are extracted from a customer by liposuction. The extraction is treated to produce a fluid purportedly rich in stem cells known as a stromal vascular fraction or SVF, which is injected back into the same subject.
Both sets of defendants asserted in their defense that their activities qualified for exceptions from FDA drug regulations afforded to surgical procedures involving the use of a patients own tissues as well as the use of minimally manipulated tissues. The agencys position is that the fat extractions are so heavily treated before the reinjections that the treatments fall outside those exceptions.
In his ruling, Bernal drew extensively and verbatim from California Stem Cell Treatment Centers proposed findings of facts and scarcely at all from the FDAs proposal. His ruling incorporated several scientific errors, according to Knoepfler.
For example, Bernal accepted the centers assertion that unlike manufactured drugs, the SVF Surgical Procedure does not create any cellular or tissue-based product that did not previously exist within the patient.
In fact, Knoepler says, there is no equivalent of SVF already in the body.
See more here:
Hiltzik: A judge undermines the FDA on stem cells - Los Angeles Times
- Overcoming Tendonitis: How Stem Cell Treatments Are Revolutionizing Athlete Rehabilitation - Medical Tourism Magazine - February 21st, 2024
- Unproven Stem Cell Treatments Offer Hope & Risks - Healthline - January 4th, 2023
- Stem Cell or Bone Marrow Transplant Side Effects - American Cancer Society - November 24th, 2022
- Stem cell: $137 million buys more clinical trials, shared labs ... - November 24th, 2022
- Stem Cells Australia | Australian research, stem cell treatments and ... - October 29th, 2022
- What is a Bone Marrow Transplant (Stem Cell Transplant)? - Cancer.Net - October 29th, 2022
- Cameron Mathison Is Undergoing Stem Cell Treatments - October 4th, 2022
- Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD - GlobeNewswire - October 4th, 2022
- 15 Years of Heart - Newswise - October 4th, 2022
- QC Kinetix (The Heights) Helping Patients Heal Better from Joint Pain Through Houston Heights Sports Medicine - Yahoo Finance - October 4th, 2022
- Sources - Minnesota Timberwolves' Karl-Anthony Towns was on bed rest for days due to throat infection - ESPN - October 4th, 2022
- Innovative spaces and an expert team help Childrens Hospital New Orleans set the standard in cancer care - NOLA.com - September 25th, 2022
- Stem Cell Transplantation: What it Is, Process & Procedure - September 16th, 2022
- New stem cell therapy provides long-term brain protection against ALS - Study Finds - September 8th, 2022
- $150 Million Gift Takes Stem Cell Research to New Heights - University of California San Diego - September 8th, 2022
- Seattle biotech company is the first to receive approval to test B cell gene therapy in humans - GeekWire - September 8th, 2022
- Kite's CAR T-cell Therapy Tecartus Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia... - September 8th, 2022
- Could Stem-Cell Based Therapy Treat Type-1 Diabetes? A New Study Demonstrates the Treatments Potential - SciTechDaily - August 30th, 2022
- Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio - GlobeNewswire - August 30th, 2022
- Global Cancer Stem Cells Market Estimated to Reach $1,722.7 Million by 2026 and Grow at 10.3% CAGR in the 2019 to 2026 Timeframe | [180-Pages] Report... - August 22nd, 2022
- Getting a Stem Cell or Bone Marrow Transplant - American Cancer Society - August 14th, 2022
- Stem cell therapy to be used in treatment of long COVID by Panacell Biotech - Labiotech.eu - August 14th, 2022
- Selma Blair 'Stopped Looking in the Mirror' After MS Treatments - TooFab - August 14th, 2022
- ElevateBio Announces the Formation of a New Company With George Daley, M.D., Ph.D., and Boston Childrens Hospital to Develop iPSC-Derived Allogeneic... - August 5th, 2022
- Stem Cells Are Needed To Treat Life-Threatening Diseases - Longevity LIVE - Longevity LIVE - July 19th, 2022
- Stem Cell Hair Transplant: What Is It and When Will It Be Available? - July 11th, 2022
- Stem cell treatments and regulation - a quick guide for consumers - July 11th, 2022
- Tisch Multiple Sclerosis Research Center of New York Study Featured in BioSpace - Business Wire - July 3rd, 2022
- NorthX Biologics expands to Cell Therapy: Partnership with Alder Therapeutics and new manufacturing site on Karolinska campus - GlobeNewswire - June 22nd, 2022
- Japan's five hottest biotech companies in healthcare - Labiotech.eu - June 22nd, 2022
- Sickle cell beta thalassemia: Causes, symptoms, and treatments - Medical News Today - June 22nd, 2022
- Umoja Biopharma Presents Data on its Engineered Induced Pluripotent Stem Cell Platform at the 2022 International Society for Stem Cell Research Annual... - June 22nd, 2022
- Six Things to Know About Stem Cell Treatment - HealthTechZone - May 15th, 2022
- CU Anschutz center for cell-based therapy gets $200 million expansion - The Denver Post - May 15th, 2022
- Differentiation therapy, Hox genes and Abemaciclib Research update 13th May - Brain Tumour Research - May 15th, 2022
- Here's the No. 1 Reason to Buy Vertex Pharmaceuticals Now - The Motley Fool - May 15th, 2022
- To help cope with the world's oldest population, Japan is investing in transplanted iPS stem cells - CBS News - April 19th, 2022
- Stem cell cure for lower back pain is all in the 'hiPS' - Study Finds - April 19th, 2022
- Versant-backed startup launches with plans to broaden cell therapy's reach - BioPharma Dive - April 19th, 2022
- CAR NK-Cell Therapy Is Quickly Growing in Immunotherapy - Targeted Oncology - April 19th, 2022
- Robert Vonderheide Appointed to Second Five-Year Term as Director of the Abramson Cancer Center - U Penn - April 19th, 2022
- Signaling Pathways and Targeted Therapies for Stem Cells in Prostate Cancer - DocWire News - April 19th, 2022
- Is Stem Cell Therapy Right for You? - Health Essentials from Cleveland Clinic - April 6th, 2022
- Cleveland Cord Blood Center and Deverra Therapeutics Announce Agreement - PR Newswire - April 6th, 2022
- Early Treatment Matters More Than Ever in Multiple Myeloma, Kumar Says - AJMC.com Managed Markets Network - April 6th, 2022
- Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives - DocWire News - March 25th, 2022
- A Holistic Review on the Current and Future Status of Biology-Driven and Broad-Spectrum Therapeutic Options for Medulloblastoma - Cureus - March 25th, 2022
- Current Strategies and the Potential of CAR T-Cell Therapy in Relapsed and Refractory MCL - AJMC.com Managed Markets Network - March 25th, 2022
- 'I wouldn't be here': Virginia girl, celebrating 11 years in remission, credits St. Jude with saving her life - News 3 WTKR Norfolk - March 25th, 2022
- This weird mouse with a tuft of human hair could be the future of a stem cell treatment for baldness - Boing Boing - January 20th, 2022
- 5 questions facing gene therapy in 2022 - BioPharma Dive - January 20th, 2022
- How Stem Cell and Bone Marrow Transplants Are Used to ... - January 5th, 2022
- The Stem Cell Transplant Process - UChicago Medicine - January 5th, 2022
- Next Chapters: How Northern California blood recipients are doing years after donors helped save their lives - KCRA Sacramento - January 5th, 2022
- Exclusive: Ronnie Coleman on Recent Weight Gain, Current Strength, and Health Progress - BarBend - January 5th, 2022
- Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent ... - KULR-TV - November 8th, 2021
- Managing superficial pyoderma with light therapy - DVM 360 - October 28th, 2021
- New Treatments and Tips for Dealing With Blood Cancer - Curetoday.com - October 28th, 2021
- Orchard Therapeutics Outlines Comprehensive Presence at the - GlobeNewswire - October 16th, 2021
- Taking aim at the brain, Takeda strikes up cell therapy R&D alliance with Immusoft - MedCity News - October 16th, 2021
- The Impact Of Market Restrictions On The US Stem Cell Biomaterials Market - Med Device Online - October 16th, 2021
- FTC Follows Through On Prioritizing Investigations Into False Advertising In Healthcare Markets - Media, Telecoms, IT, Entertainment - United States -... - October 16th, 2021
- FDA Warns About Stem Cell Therapies | FDA - October 5th, 2021
- Anja Health Disrupts Cord Blood Banking with Heartfelt Founding Story and Ground-Breaking Mission - Digital Journal - October 5th, 2021
- Kite's Tecartus is First CAR T Therapy Approved for Adults with B-Cell ALL - Clinical OMICs News - October 5th, 2021
- Prolymphocytic Leukemia: What Is It and How Is It Treated? - Healthline - August 31st, 2021
- Researchers Gaze into Space to Envision Future of Regenerative Medicine - UPMC & Pitt Health Sciences News Blog - UPMC - August 18th, 2021
- Acute Myeloid Leukemia Treatment: What You Need to Know - Healthline - August 18th, 2021
- Study Calls for COVID-19 Vaccination in Patients With Cancer to Enable Optimal Treatment Delivery During Pandemic - OncLive - August 18th, 2021
- A Third Dose of the COVID-19 Vaccine Recommended for Some Cancer Patients With Weakened Immune Systems - On Cancer - Memorial Sloan Kettering - August 18th, 2021
- Stem cells: What they are and what they do - Mayo Clinic - June 6th, 2021
- Stem Cell Therapy for Knee Pain: What Patients Should Know - June 6th, 2021
- Study clarifies the impact of getting old on hematopoietic stem cells - Microbioz India - December 26th, 2020
- Stem Cell Therapy Shows 2-year Benefit for Progressive MS Patients in Phase 1 Trial - Multiple Sclerosis News Today - December 22nd, 2020
- New Combination Therapy Tested By Children's May Offer Hope For Leukemia Patients - WVXU - December 22nd, 2020
- Physio Logic Brings Cutting-edge Regenerative Treatments for Sport Injuries and Arthritis to New York City - PRNewswire - December 22nd, 2020
- For Patients With HMA-Resistant MDS, What Are Their Options? - AJMC.com Managed Markets Network - December 22nd, 2020
- In COVID-19 Clinical Trials, Experts from Baptist Health's Cancer Institutes Treat Patients With Mild or Severe Symptoms - Baptist Health South... - December 22nd, 2020
- SPONSORED: 12 Charities of Christmas - Anthony Nolan - The Courier - December 22nd, 2020
- California's Proposition 14: short in the arm for stem cell research - BioNews - December 14th, 2020